Navigation Links
Agent that triggers immune response in plants is uncovered
Date:10/4/2007

Although plants lack humans' T cells and other immune-function cells to signal and fight infection, scientists have known for more than 100 years that plants still somehow signal that they have been attacked in order to trigger a plantwide resistance. Now, researchers at the Boyce Thompson Institute for Plant Research (BTI) on the Cornell campus have identified the elusive signal in the process: methyl salicylate, an aspirin-like compound that alerts a plant's immune system to shift into high gear.

This phenomenon is called systemic acquired resistance and is known to require movement of a signal from the site of infection to uninfected parts of the plant.

The findings are published in the Oct. 5 issue of Science.

"By finally identifying a signal that moves from an infection site to activate defenses throughout the plant, as well as the enzymes that regulate the level of this signal, we may be in a position to alter the signal in a way that enhances a plant's ability to defend itself," said BTI senior scientist Daniel F. Klessig, an adjunct professor in plant pathology at Cornell, who conducted the work with Sang-Wook Park and other BTI colleagues.

Their approach, using gene technology to enhance plant immunity, could have wide consequences, boosting crop production and reducing pesticide use.

Methyl salicylate is a modified form of salicylic acid (SA), which has been used for centuries to relieve fever, pain and inflammation, first through the use of willow bark and, since 1889, with aspirin, still the most widely used drug worldwide.

In the 1990s, Klessig's research group reported that SA and nitric oxide are two critical defense-signaling molecules in plants, as well as playing important roles in human health. Then, in 2003 and 2005, the group reported in the Proceedings of the National Academy of Sciences that an enzyme, salicylic acid-binding protein 2 (SABP2), is required for systemic acquired resistance and converts methyl salicylate (which is biologically inactive as it fails to induce immune responses) into SA, which is biologically active.

After plants are attacked by a pathogen, the researchers had previously found, they produce SA at the infection site to activate their defenses. Some of the SA is converted into methyl salicylate, which can be converted back into SA by SABP2.

Using plants in which SABP2 function was either normal, turned off or mutated in the infected leaves or the upper, uninfected leaves, Klessig's group showed that SABP2 must be active in the upper, uninfected leaves for systemic acquired resistance to develop properly. By contrast, SABP2 must be inactivated in the infected leaves by binding to SA.

"This inactivation allows methyl salicylate to build up," explained Klessig. "It then flows through the phloem (or food-conducting "tubes") to the uninfected tissue, where SABP2 converts it back into active SA, which can now turn on the plant's defenses."

Klessig said that it is unclear why plants send this hormone to uninfected tissue in an inactive form, which then must be activated by removal of the methyl group.

"This research also provides insight into how a hormone like SA can actively regulate its own structure -- and thereby determine its own activity -- by controlling the responsible enzyme," noted Park, the lead author of the paper.


'/>"/>

Contact: Blaine Friedlander
bpf2@cornell.edu
607-254-8093
Cornell University News Service
Source:Eurekalert

Related biology news :

1. New drug shows promise as powerful anticancer agent
2. To control germs, scientists deploy tiny agents provocateurs
3. Gadonanotubes greatly outperform existing MRI contrast agents
4. Tiny avalanche photodiodes target bioterrorism agents
5. Software agents could help unmask reality of disease clusters
6. Mouse study: New muscle-building agent beats all previous ones
7. Chemical warfare agent detection technology used to treat lung disease
8. Got inexpensive contrast agent? Milk plays new role in imaging
9. Trojan Horse agent halts bone metastasis in mice
10. Failed experiment yields a biocontrol agent that doesnt trigger antibiotic resistance
11. Gallium: A new antibacterial agent?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, ... held genomics technology company, announced today that on December ... Qualifications Department of The Nasdaq Stock Market LLC which ... bid price of WaferGen,s common stock had been at ... WaferGen has regained compliance with Listing Rule 5550(a)(2) of ...
(Date:12/15/2016)... Dec. 14, 2016 "Increase in mobile transactions ... The mobile biometrics market is expected to grow from ... by 2022, at a CAGR of 29.3% between 2016 ... as the growing demand for smart devices, government initiatives, ... "Software component is expected to grow at a ...
(Date:12/7/2016)... -- According to a new market research report "Emotion Detection and ... Recognition), Service, Application Area, End User, And Region - Global Forecast to 2021", ... Billion in 2016 to USD 36.07 Billion by 2021, at a Compound Annual ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... Jan. 18, 2017 The global biotechnology ... 92.9 billion by 2025, according to a new ... has been adaptive of the function of outsourcing ... 2002. Among the services outsourced, clinical trial management ... Johnson & Johnson was the first pharmaceutical company ...
(Date:1/19/2017)... BD (Becton, Dickinson and Company) (NYSE: BDX ), a ... live webcast of its Annual Meeting of Shareholders on Tuesday, January ... can be accessed from the BD corporate website at http://www.bd.com/investors/ ... ... BD is a global medical technology company that is ...
(Date:1/18/2017)... , Jan. 18, 2017   Boston Biomedical ... compounds designed to target cancer stemness pathways, will feature ... compound, napabucasin, at the 2017 ASCO Gastrointestinal Cancers Symposium, ... . Napabucasin is an orally-administered ... targeting STAT3. i Cancer stem cells (CSCs) possess ...
(Date:1/18/2017)... , ... January 18, 2017 , ... ... Clinical Ops Executives 2017 in its continued commitment to the advancement of the ... to discuss current issues related to clinical trial planning and management. , ...
Breaking Biology Technology: